<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>21 Paediatrics</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part26.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part28.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark27" class="s17" name="bookmark73">Chapter 21</a><a name="bookmark74">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_314.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark27">Paediatrics</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;line-height: 111%;text-align: left;">mark Gaze, monique shahid, paul humphries, and Francesca peters</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 12pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There are various definitions of what constitutes ‘paediatric’ or ‘adolescent’ patients, and the terms ‘children’, ‘teenagers’, and ‘young people’ are sometimes used loosely. In its guidance, <i>Improving Outcomes in Children and Young People with Cancer</i>, the National Institute for Health and Care Excellence regards those aged less than 15 years as children, and those aged 15–24 as young people. The Children’s Cancer and Leukaemia Group reports patients aged up to 15 years separately from those 15 years and older, so in this chapter the age of 15 years will be taken as the cut-off point.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Paediatric cancer is a diverse and heterogeneous group of diseases. Table 21.1 sets out the principal categories of malignant disease, and their relative proportion, in chil- dren. Although there are cancer types which usually occur in those under 15, and other types which almost always occur in individuals aged over 15 years, there are exceptional cases when cancers occur in the ‘wrong’ age group, and there are other cancer types which commonly affect both children and older patients.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Paediatric malignancy is uncommon, with less than 1% of all cancers seen in chil- dren less than 15 years of age. Between 2001 and 2005, there were 21,289 registered cases of cancer (including non-malignant intracranial and intraspinal tumours) in children under the age of 15 in England, equating to an incidence of 1420 new regis- trations per year.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">21.2 <span class="h4">The role of imaging in paediatric oncology</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Timely access to appropriate diagnostic imaging, including nuclear medicine, is es- sential in children and young people with suspected or confirmed malignant disease. Imaging has a number of roles which include:</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Assessment of a suspicious lesion, with the aim of providing a differential diagnosis and guiding an interventional radiology biopsy procedure which may avoid the need for an open surgical biopsy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Staging the local extent of disease and identifying nodal or distant metastases.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Assessment of response to therapy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Target volume definition for radiotherapy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Management of complications and late effects.</span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 21.1 <span class="s25">Approximate relative frequency of paediatric cancer types</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:15pt"><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Leukaemia</p></td><td style="width:138pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">30%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Acute lymphoblastic leukaemia</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">25%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">other leukaemias</p></td><td style="width:138pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">5%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Central nervous system tumours</p></td><td style="width:138pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">26%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Low grade astrocytoma</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">12%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Cns embryonal tumours</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">7%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">other central nervous system tumours</p></td><td style="width:138pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">7%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Lymphoma</p></td><td style="width:138pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">11%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">hodgkin lymphoma</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">6%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">non-hodgkin lymphoma</p></td><td style="width:138pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">5%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Non-central nervous system solid tumours</p></td><td style="width:138pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s129" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">33%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">neuroblastoma</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">6%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">soft tissue sarcoma</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">6%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">renal tumours</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">6%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Bone sarcomas</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">4%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">retinoblastoma</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">3%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Germ cell tumours</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">3%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">melanoma and carcinomas</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">3%</p></td></tr><tr style="height:16pt"><td style="width:185pt"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Liver tumours</p></td><td style="width:138pt"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">1%</p></td></tr><tr style="height:15pt"><td style="width:185pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">other types</p></td><td style="width:138pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">1%</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There are many challenges to overcome when imaging children, particularly in the setting of malignant disease. The inherent heterogeneity of the population of ‘paediatric’ patients in terms of age, body size, and understanding and tolerance of imaging procedures, demands a flexible and age-appropriate approach, and re- inforces the need for paediatric radiologists, trained in oncology imaging, in paedi- atric oncology centres.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Simply being in hospital can be bewildering and frightening for any child. It is worse if the child is unwell or in pain, or has had prior experience of distressing procedures. It is important to engage with both the child and their parents to facili- tate a successful examination. Older children can cooperate with imaging investi- gations when the purpose and practicalities of the procedure are simply explained. In younger children, the input of a hospital play specialist and the use of distraction techniques (e.g. the use of toys, books, or videos) are particularly useful. Sometimes adopting a non-standard scanning position, for example with the child being cuddled by a parent or carer, may facilitate ultrasound (US) examinations. In younger chil- dren, especially if the scan time is long, as with magnetic resonance imaging (MRI),</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">or when it is not advisable for a parent to remain in the room during the procedure, the use of sedation or general anaesthesia is required.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In general terms, the use of ionizing radiation investigations should be kept to a minimum. This is because of the greater radiosensitivity of children and their ex- pected longer lifespan in which radiation effects, especially carcinogenesis, have a longer time to manifest themselves. To this end there is a greater emphasis on non- ionizing techniques, with US and MRI being utilized where possible. Where ionizing techniques (such as computed tomography (CT) or positron emission tomography (PET)) are needed, radiation dose reduction strategies are employed in order to min- imize exposure.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">US enables real-time evaluation and is particularly helpful with abdominal masses in assessing their relationship with solid organs and vessels. MRI provides excellent anatomical detail without the use of ionizing radiation, and although central nervous system (CNS) imaging is relatively straightforward, MRI of body tumours remains a challenge in paediatric practice.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Particular difficulties include:</p><p class="s23" style="padding-top: 3pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Relatively long scan times (compared with multislice CT), leading to motion artefact.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Relatively poor signal-to-noise ratio of the images when patients are small in size, necessitating innovative use of ‘adult’ coils, for example using knee coils or flex coils to image abdominal tumours in infants.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Inherent low image quality of chest MRI, owing to low signal generated and arte- fact from respiratory and cardiac motion.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Issues related to patients tolerating the MRI examination, including patient co- operation, particularly in those under six years of age.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Logistical difficulties may occur in relation to radiotherapy planning and delivery as patients are often imaged in a number of separate hospitals. For example, a tumour may be imaged at presentation to a district general hospital, and further imaging may be performed at the paediatric oncology centre, whereas radiotherapy may be planned and administered at a third separate hospital. It is important for the clin- ical oncologist to have all relevant imaging to enable accurate target volume defin- ition. For different cancers, treatment may be planned on the extent of disease at diagnosis or following initial chemotherapy, or on the presurgical tumour or the postoperative residual mass. Digital imaging sent in DICOM format on a disc, or by image exchange software, is preferable to hardcopy images as it can be uploaded into radiotherapy planning computers, and fused with other images. It is essential to have adequate administrative staff to locate and retrieve the required images from other hospitals in order to avoid unnecessary re-imaging of children simply be- cause previous imaging is not to hand. Patients should be discussed at the relevant multidisciplinary team meeting; this allows patients to be considered from a range of viewpoints and expertise, and offers a greater probability of timely, appropriate treatment and better continuity of care.</p><p class="s19" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.3 <span class="h4">CNS tumours</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.3.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">As a group, CNS tumours are the second most common paediatric malignancy after leukaemia. Clinical presentation includes:</p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Symptoms of raised intracranial pressure, including headaches and vomiting, which is often due to the development of obstructive hydrocephalus.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">Focal neurological signs including cranial nerve palsies or a hemiparesis.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Epileptic manifestations of various sorts including complex partial seizures and grand mal convulsions are an uncommon presentation.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Infants may present with increasing head circumference, lethargy, and nausea and vomiting.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Pituitary, suprasellar, and hypothalamic tumours may present with a variety of symptoms, including visual loss, appetite disturbance, precocious or delayed pu- berty, growth failure, or other endocrine dysfunction.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Back pain, scoliosis, pyramidal tract signs, and flaccid paralysis may be presenting features in those with spinal tumours and metastases.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">21.3.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The first step in the differential diagnosis of a CNS tumour is to define its anatomical location. Anatomically, CNS tumours can be considered as infra- or supratentorial. Supratentorial tumours are more common in ages 1–3 years, infratentorial (posterior fossa) tumours more common in ages 4–10 years. Tumours within an infratentorial location decrease in proportion with increasing age, whilst tumours located within the supratentorial brain and meninges increase in proportion, with an equal distribution over ten years of age. Primary spinal cord tumours are very rare.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Both CT and MRI can be utilized in the investigation of a child with a suspected CNS tumour. CT, by virtue of its wider availability and shorter scanning times, is often used as the first or screening investigation. It may confirm the presence of a tumour and associated features such as obstructive hydrocephalus. CT is relatively more sen- sitive for the detection of calcification, which may be seen in craniopharyngiomas. Subsequent MRI is required if an abnormality is shown. MRI has the advantage of defining the location and extent of tumour more accurately, and is very sensitive to the presence of blood products. More specialized MRI techniques, such as magnetic resonance spectroscopy (MRS) and perfusion imaging may be utilized, whereby MRS can aid in differentiating normal tissue from tumour, and perfusion imaging enables identification of neovascularization associated with tumour angiogenesis. While spinal metastases are most common in medulloblastoma and other embry- onal tumours, germ cell tumours, and ependymoma, MRI of the spine should be performed in all patients with brain tumours as spinal metastatic disease, although less common, can occur in almost all brain tumour types including both high-grade and low-grade gliomas.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">While imaging including CT, diffusion-weighted MRI, and MRS may give a strong indication of the type of tumour, in most cases surgery or at least a biopsy is essential to define its histological type.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Possible exceptions to this general rule include:</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Diffuse intrinsic pontine gliomas which have characteristic MRI appearances and where biopsy may be hazardous (Figure 21.1), although this is being performed in clinical trials to evaluate the molecular pathology.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Bifocal midline masses in the pineal and suprasellar regions with normal blood and cerebrospinal fluid (CSF) tumour markers which are diagnostic of germinoma.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">A midline mass associated with significantly elevated levels of the tumour markers αFP (alpha-fetoprotein) and/or βHCG (beta-human chorionic gonadotrophin) in blood or CSF, diagnostic of a secreting intracranial germ cell tumour.</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For the majority of primary tumours, complete surgical resection is attempted when it is believed that this can be achieved without undue morbidity, with intraoperative MRI being increasingly used in many centres allowing the neurosurgeon to perform image-guided surgical navigation. Otherwise limited surgery such as cyst aspiration or biopsy only is indicated because of the morbidity which would be associated with rad- ical surgery, and the effectiveness of non-surgical treatment. Where a lesion is difficult to access, MRI or CT-guided biopsy may be helpful.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Following surgery for a brain tumour, a postoperative MRI scan with gadolinium should be performed to assess the extent of residual disease. This is particularly im- portant as a surgeon’s intraoperative judgement about the completeness of removal may be wrong. It is important to image the spine at this point in time if it was not done preoperatively in those tumour types where there is any risk of metastasis. This in- cludes gliomas of all types as well as intracranial germ cell tumours, ependymomas, and medulloblastoma and other central nervous system embryonal tumours. It is important</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="339" height="193" alt="image" src="Image_315.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.1 <span class="s25">(a) Axial t2-weighted image of a brainstem glioma, showing marked swelling and signal change of the pons, with abnormal signal extending into both cerebellar peduncles (short arrows). (b) sagittal t2-weighted image of a brainstem glioma causing expansion of the pons and medulla, with marked effacement of the iV ventricle (short arrow).</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">to perform postoperative MRI within 48 hours, as beyond that time it can be more diffi- cult to distinguish between residual or metastatic disease and surgical artefact. Risk strati- fication depends on the extent of postoperative residual disease in medulloblastoma, and this affects clinical trial eligibility and the radiotherapy dose prescribed.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.3.3 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients will have a CT scan performed, usually with intravenous contrast, in the treat- ment position in their immobilization shell in the radiotherapy department. This will be of head only when localized cranial radiotherapy is to be given, or of the head and whole spine if craniospinal radiotherapy is necessary (Figure 21.2). Image fusion of pre- and/or postoperative MRI scans will help with target volume definition. Contrast</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="397" height="358" alt="image" src="Image_316.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.2 <span class="s25">radiotherapy images. medulloblastoma, germ cell tumours, and other central nervous system tumours with leptomeningeal metastases require whole Cns radiotherapy. (a) planning drr shows the lateral head field covering the brain and cervical spine. the clinical target volume covers the meninges and its reflections and a margin is added to define the ptV. Care is taken to ensure adequate coverage of the cribriform plate area anteriorly which means that the eyes cannot be fully shielded.</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">(b) planning drr shows the field covering the whole spine. Care is taken to ensure a precise match with the cranial fields, and to ensure adequate coverage of the spinal theca inferiorly. (c) planning drr of the lateral phase ii field covering the suprasellar intracranial germ cell tumour. (d) planning drr of the phase ii anterosuperior field.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">administration may be helpful, especially if there is an incompletely resected tumour. For localized tumours, the gross tumour volume (GTV) is usually the area of gado- linium enhancing tumour without surrounding oedema. The clinical target volume (CTV) is the GTV plus a defined margin depending on tumour type as below, or ex- tended to the meninges. The margin for the planning target volume (PTV) will depend on the results of departmental audits of movement within the shell, but will usually be of the order of 3–5 mm.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.3.4 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A baseline post-treatment MRI scan with gadolinium enhancement should be per- formed about six weeks after completion of treatment. This may be brain-only for tumours without metastatic potential such as craniopharyngioma, but should be of the whole CNS in tumour types which have potential for seeding through the CSF pathways such as medulloblastoma and germ cell tumours. Routine follow-up imaging is performed at 3–6-monthly intervals, usually until five years have elapsed. Interval scans will be required if new symptoms develop. The first symptoms of a recurrence or second tumour may precede imaging changes and so despite a previous normal scan a second scan after an interval of 4–6 weeks should be considered. If there is a clinical suggestion of raised intracranial pressure, a non-contrast CT scan may be adequate as an emergency investigation to confirm or exclude the development of obstructive hydrocephalus.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">21.4 <span class="h4">Renal tumours</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.4.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Wilms’ tumour or nephroblastoma is the most common renal tumour in childhood and arises from mesodermal precursors of the renal parenchyma. The peak incidence is between three and four years of age, with 80% of affected children being under five years of age. There is an equal sex distribution. It typically presents as an asymptom- atic abdominal mass or with pain and fever. Bilateral tumours are seen in approxi- mately 10% of cases, with two-thirds of these being synchronous. Approximately 15% of treated patients will relapse, with the majority occurring within two years after nephrectomy.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There are several associated conditions that predispose to the development of Wilms’ tumour, including:</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Beckwith-Wiedemann (10–20% risk of Wilms’ tumour)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Denys-Drash</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Perlman</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">WAGR syndromes</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Nephroblastomatosis is the persistence of multiple immature nephrogenic rests within the kidney. These should normally involute after 36 weeks of gestation. It is thought to be a precursor to the development of Wilms’ tumour and is associated with a number of conditions including trisomies 13 and 18, Beckwith-Wiedemann and Denys-Drash syndromes. It is seen in up to 40% of unilateral, and in nearly</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">all cases of multicentric or bilateral, Wilms’ tumour. In the UK, children with an associated condition having risk of developing Wilms’ tumour of 5% or more are screened using ultrasound every three months until the age of seven years. The interval accounts for the doubling rate of Wilms’ tumour (ten days) and the sensi- tivity of abdominal ultrasound.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Rarer histologies of renal tumours in childhood include clear cell sarcoma of the kidney, malignant rhabdoid tumour, mesoblastic nephroma, and renal cell carcinoma.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.4.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">At US examination, Wilms’ tumour typically appears as a mass with increased echogenicity, with or without cystic areas (owing to central necrosis and cyst for- mation). US is particularly useful in evaluating the renal vein and IVC for tumour extension. The contralateral kidney should be examined for a synchronous lesion or nephroblastomatosis. On cross-sectional imaging it is seen to arise from the kidney, classically with a ‘claw’ of normal renal tissue seen stretched around the periphery of the tumour. Wilms’ tumour typically displaces, rather than encases, vessels in contrast to neuroblastoma (Figure 21.3). MRI may have a role in differentiating hyperplastic nephroblastomatosis and Wilms’ tumour from sclerotic (regressive) nephroblastomatosis.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A percutaneous needle biopsy may be performed to confirm the diagnosis and characterize the pathological tumour type, but current guidelines developed by the International Society of Paediatric Oncology (UMBRELLA SIOP-RTSG 2016) recom- mend that infants under six months of age presenting with a renal mass should be con- sidered for primary surgery, with percutaneous biopsy only recommended in instance of stage IV disease or when immediate surgery is deemed difficult.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Approximately 17% of patients with Wilms’ tumours present with stage IV dis- ease with pulmonary metastases being most common. Chest CT is now the standard</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="184" alt="image" src="Image_317.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.3 <span class="s25">Contrast-enhanced Ct of left Wilms’ tumour with: (a) left renal vein (short arrow) and iVC tumour thrombosis (arrowheads); (b) tumour thrombus also extends into the right renal vein (long arrow)—stage 2 or 3 determined by complete/incomplete surgical resection respectively.</span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 21.2 <span class="s25">staging system for Wilms’ tumour (siop protocol)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_318.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_319.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_320.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 164%;text-align: left;">stage i   tumour is confined to the kidney and completely excised stage ii   tumour extends beyond the kidney but completely excised</p><p class="s41" style="padding-bottom: 1pt;padding-left: 58pt;text-indent: -46pt;line-height: 112%;text-align: left;">stage iii   tumour incompletely excised with either microscopic or macroscopic residual disease, or with lymph node involvement within the abdomen or pelvis</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_321.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 1pt;padding-left: 58pt;text-indent: -46pt;line-height: 112%;text-align: left;">stage iV   presence of haematogenous metastases (such as lung, bone, liver, brain) or metastases to distant lymph nodes beyond the abdomen or pelvis</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_322.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">stage V   Bilateral renal involvement at the time of initial diagnosis</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_323.png"/></span></p><p class="s21" style="padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">source: data from Vujani<span class="s71">ć</span>, Gm et al. ‘revised international society of paediatric oncology (siop) working classification of renal tumors of childhood’. <i>Med. Pediatr. Oncol</i>., Vol. 38, issue 2, pp.79–82. (2002) John Wiley &amp; sons.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">imaging for staging and will identify small pulmonary nodules too small to be de- tected by chest X-ray (CXR). CT lung nodules are only treated as metastases if their transverse diameter is at least 3 mm.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Preoperative chemotherapy is utilized to reduce both tumour size and chance of tu- mour rupture at surgery. Pathology of the resected tumour is very important for two reasons: to determine the local disease stage (Table 21.2) and to assign the patient to a pathological risk group. The pathological risk groups are low, intermediate, or high, and together with the stage determine the details of postoperative therapy.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.4.3 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy to the flank or abdomen and pelvis is indicated in Wilms’ tumour in the case of stage III intermediate or stage II or III high-risk disease (Figure 21.4), and to the thorax in patients with lung metastases which have not resolved completely with preoperative chemotherapy. The use of abdominal radiotherapy in stage IV and stage V disease is dependent on the local extent of disease.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">When radiotherapy is required for the treatment of pulmonary metastases, the whole of both lungs is treated, regardless of the number and extent of metastases.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In the current era, even though treatment techniques are usually still simple anterior and posterior parallel opposed fields, CT planning is used. This allows fusion with earlier diagnostic MR or CT images for accurate target volume definition based on the preoperative tumour extent.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.4.4 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Early detection of local recurrence or distant metastases is the purpose of imaging at follow-up. CXR should be obtained every nine weeks during treatment. The current SIOP surveillance protocol for localized and metastatic disease recommends CXR and abdominal ultrasound every three months for the first two years, with ongoing surveillance according to national guidance, usually repeated every 4–6 months in the third and fourth year. Follow-up should then stop five years after the end of treatment.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="216" alt="image" src="Image_324.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.4 <span class="s25">radiotherapy anterior beams eye view images for a patient with unfavourable histology stage iV (local stage iii) Wilms’ tumour, who has received pre-operative chemotherapy and surgery, requiring radiotherapy to the whole lungs and left flank.</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">An anterior/posterior parallel opposed technique is used. the lungs and ptV margin are shown (long arrows). target volume definition for the primary tumour and ptV margin was based on the extent of the tumour and kidney prior to operation (short arrows). panel (a) shows the phase i main field, prescribed dose 15 Gy in 10 fractions, shaped by multi-leaf collimators, covering both the primary tumour bed and metastatic site. panel</p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">(b) shows a segment field used to homogenise the dose distribution. panel (c) shows the phase ii field, on a digitally reconstructed radiograph showing the bone structure and the primary tumour ptV, again shaped by multi-leaf collimators, which extends medially across the midline to cover the full width of the vertebral bodies and para-aortic lymph node region, prescribed dose 10.5 Gy in 7 fractions (total dose to tumour bed 25.5 Gy in 17 fractions).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.5 <span class="h4">Neuroblastoma</span></p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.5.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Neuroblastoma arises from neural crest cells in the sympathetic chain. The most common primary site is in the adrenal medulla or elsewhere in the retroperitoneum, about 60%. Less commonly it arises in the posterior mediastinum (20%), or rarely in the neck, pelvis, or with no identifiable primary tumour. The median age at diagnosis is approximately 16 months with 95% of cases diagnosed by seven years of age. Rarely, it may present in teenagers and young adults. The disease shows marked heterogen- eity, with age at presentation, stage of disease, and tumour biology affecting outcome. Tumour behaviour is highly variable, with some being aggressive, whilst others, typic- ally in infancy, may spontaneously regress.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The clinical presentation depends on the site of the primary disease, loco-regional extent, and any metastatic spread (Figure 21.5). The most common presentation is with an abdominal mass. Often the tumour grows through the intervertebral for- amina, forming a dumb-bell tumour which may lead to spinal cord compression or</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="307" height="228" alt="image" src="Image_325.gif"/></span></p><p class="s24" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.5 <span class="s25">post-gadolinium t1-weighted axial mri of left suprarenal neuroblastoma (short arrows) with no involvement of coeliac axis (arrowhead) or splenic artery (long arrow)— stage L1 (inrGss).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">radiculopathy. Metastatic disease may present as bone pain, symptoms of marrow infiltration, fever, and malaise. Infantile metastatic neuroblastoma can present with multiple skin lesions, the so-called ‘blueberry muffin’ appearance. Asymptomatic pres- entation is not uncommon. Adrenal masses may be found on antenatal ultrasonog- raphy or during investigation of other problems, and thoracic neuroblastoma may be detected incidentally on chest radiography.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.5.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US typically reveals a heterogeneous solid mass, separate from and often displacing the ipsilateral kidney. Further staging investigations include bone marrow trephine, CT or MRI, depending on local availability and <span class="s22">123</span>I labelled metaiodobenzylguanidine (mIBG) scintigraphy to evaluate the primary tumour and metastases. The classical imaging appearance of abdominal neuroblastoma is that of a large soft tissue mass encasing vascular structures (Figure 21.6), with calcification seen in approximately 80% on CT. MRI better delineates extradural intraspinal extension of tumour and bone marrow involvement than CT, with the added advantage of lack of ionizing radi- ation, and is becoming more widely utilized.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Staging uses the International Neuroblastoma Risk Group (INRG) staging system: stage L1 is a locoregional tumour that does not involve vital structures as de- fined by the list of image defined risk factors. A stage L2 tumour is a locoregional tumour where there is presence of one or more image defined risk factors. Stage M is distant metastatic disease, with the exception of stage MS. Stage MS is metastatic dis- ease in children under the age of 18 months, with metastatic disease confined to skin and/or liver and/or bone marrow.<span class="s22">1</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">This is based on objective radiological staging, at diagnosis, rather than previous sys- tems which have used a post-surgical system. Disease extent is determined by Image</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="214" alt="image" src="Image_326.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.6 <span class="s25">Contrast-enhanced Ct of neuroblastoma (short arrows) encasing and displacing the aorta (arrowhead), renal vessels, coeliac artery and its branches—stage L2 (inrGss).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Defined Risk Factors (IDRF) at diagnosis. Various radiological features seen in neuro- blastoma predict for incomplete resection or a greater possibility or surgical complica- tions, and are referred to as image defined risk factors or IDRF.<span class="s22">1 </span>These include:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">When disease extends across two adjacent body compartments.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When disease in the neck: encases major blood vessels such as the carotid or ver- tebral arteries or the internal jugular vein; extends to the skull base; or compresses the trachea.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When disease at the cervico-thoracic junction: encases brachial plexus roots; encases major blood vessels such as the subclavian vessels, the vertebral, or carotid arteries; or compresses the trachea.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When disease in the thorax encases the aorta or its major branches; compresses the trachea or principal bronchi; a lower mediastinal tumour infiltrates the costovertebral junction between T9 and T12.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">When tumour encases the aorta or vena cava in the thoraco-abdominal region.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When within the abdomen or pelvis, tumour infiltrates the porta hepatis; infil- trates branches of the superior mesenteric artery at the mesenteric root; encases the origin of the coeliac axis, the superior mesenteric artery, the aorta, inferior vena cava, or the iliac vessels; invades a renal pedicle; crosses the sciatic notch.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When at any vertebral level, a dumb-bell tumour invades more than one third of the spinal canal in the axial plane; the perimedullary leptomeningeal spaces are not visible; or the spinal cord signal is abnormal.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When the disease involves or infiltrates adjacent organs or structures, for example pericardium, diaphragm, kidney, liver, duodeno-pancreatic block, mesentery, and others.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="139" alt="image" src="Image_327.gif"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.7 <span class="s25">metastatic neuroblastoma in a 15-month-old infant. (a) Coronal t2 spACe of left suprarenal neuroblastoma (short arrows) with liver metastases (arrowheads).</span></p><p class="s25" style="padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">(b) miBG study demonstrated multifocal bone uptake within the left mandible, supraorbital regions and skull base (short arrows)—stage m (inrG staging system).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The presence of multifocal primary tumours, pleural effusion, or ascites, with or without malignant cells should be recorded, but these are not considered to be IDRF.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Metastatic disease is defined as any disease spread that is not in continuity with the primary tumour, including non-contiguous lymph node spread. The new stage MS (previously stage 4S) now has an upper age limit of 18 months (Figure 21.7), as the benefit of young age extends beyond infancy. Biopsy of the primary tumour is under- taken at diagnosis to evaluate the histology and cell ploidy of the tumour and deter- mine if <i>MYCN </i>amplification is present. Approximately 20% of cases will demonstrate <i>MYCN </i>amplification, which is associated with metastatic disease and a poorer prog- nosis. A combination of INRG staging system, age of the patient (younger or older than 18 months), <i>MYCN </i>status, and histology define the risk group for each case, which determines the treatment received.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.5.3 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The treatment of neuroblastoma involves complex multimodality therapy including surgery, chemotherapy, radiotherapy, and biological treatments, and the precise treat- ment schedule is dependent on risk-group assignment. Radiotherapy is indicated to the primary tumour site in all patients with high-risk disease, that is to say children over 18 months of age with stage M disease, and in patients with <i>MYCN </i>amplified disease stage L2 or M regardless of age (Figure 21.8). Selected patients with intermediate-risk disease, those <i>MYCN </i>non-amplified stage L2 aged over 18 months with undifferen- tiated histology, should also receive radiotherapy to the primary site. Patients with low-risk disease, principally those with L1, L2, or MS disease under 18 months of age without <i>MYCN </i>amplification are managed with much less intensive treatment, sur- gery, or chemotherapy alone or in combination, or sometimes observation alone in the hope of spontaneous regression.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Target volume definition for radiotherapy in the local control of the primary tu- mour in patients with high-risk neuroblastoma and intermediate-risk disease is based</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">on the post-chemotherapy, pre-surgery, extent of the tumour. Patients will be as- sessed by contrast-enhanced CT or MRI following induction chemotherapy. It is often easier to define the full extent of the disease on contrast enhanced CT, than on MRI. Subsequently patients will undergo resection of their tumour if operable and often high-dose chemotherapy also, so an interval of three months may elapse before they</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="417" alt="image" src="Image_328.jpg"/></span></p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(g)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(g)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(g)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(h)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(h)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(h)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(i)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(i)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(i)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.8 <span class="s25">radiotherapy target volume delineation for a right suprarenal neuroblastoma: (a) axial; (b) sagittal; and (c) coronal Ct images to demonstrate the size and location of the tumour at diagnosis. (d) axial, (e) sagittal, and (f) coronal Ct images to show a much smaller tumour following induction chemotherapy prior to surgery. (g) axial, (h) sagittal, and (i) coronal planning Ct scan images following surgery</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">and high-dose chemotherapy. the bulk of the tumour has gone, but some pathological calcification remains. Virtual gross tumour volume (GtV) was based on images d, e, and f, cut back to barriers of spread where previously displaced organs had returned</p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">to a more normal position, and modified by the surgical and pathology reports (purple outline and arrows). Clinical target volume (CtV) grown from GtV by 0.5 cm except over vertebrae (pink outline and arrows). planning target volume (ptV) grown from CtV by</p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">0.5 cm (red outline and arrows).</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">are ready for radiotherapy. A planning scan done at this time may be fused with the earlier scan. The initial scan is used to define the virtual GTV, based on the extent of the primary tumour and any contiguous nodal spread. A 0.5–1 cm margin is added to define the CTV which may be modified to include whole vertebrae to avoid the devel- opment of a scoliosis and to allow for uninvolved organs such as liver which may have moved into the space previously occupied by tumour. To minimize irradiation of crit- ical normal structures such as the contralateral kidney the CTV may be reduced again. The radiotherapy planning scan is also used to define organs at risk (OAR), including the kidneys, liver, and lungs.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The art of target volume definition in paediatric radiotherapy is to achieve the best balance between full coverage of the tumour and avoidance of OAR. Sometimes it is necessary to compromise on the recommended protocol treatment of the tumour with regard to total dose, volume, or both, to reduce the risk of unacceptable normal tissue damage.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.5.4 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In addition to standard cross-sectional imaging, <span class="s22">123</span>I-mIBG scintigraphy is im- portant to assess the response to therapy of metastatic disease. Semi-quantitative scoring systems are used. New criteria to assess response to therapy have been de- scribed. In these, the extent of disease, and the response, in three separate compart- ments: bone, bone marrow, and soft tissue, are separately evaluated. The responses seen in these three components are then combined to give an overall response (Figure 21.9).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">21.6 <span class="h4">Lymphoma</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.6.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lymphoma arises from lymphatic cells and approximately half are Hodgkin lymphoma (HL) and half non-Hodgkin lymphoma (NHL). Radiotherapy is important in the man- agement of HL, but the treatment of NHL in childhood is almost exclusively chemo- therapy. The rest of this section therefore relates only to HL.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The most typical clinical presentation is with painless cervical or supraclavicular lymphadenopathy. At least two thirds of patients will have some degree of mediastinal involvement which may be detected incidentally on a CXR taken for other reasons. Systemic symptoms such as fever, night sweats, and weight loss may also be present.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.6.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Initial imaging investigations usually include a CXR and US of both the neck and abdomen, including high-resolution US imaging of the liver and spleen to assess for small focal lesions. Cross-sectional imaging has a central role in staging, as the ana- tomical extent of disease at diagnosis has a profound impact on management and out- come. Imaging of the neck, abdomen, and pelvis can be performed with either CT or MRI. The chest should be imaged using CT, as current MRI techniques are not</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s104" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">PD</p><p class="s14" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">Any component with PD</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s104" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">CR</p><p style="text-indent: 0pt;text-align: left;"><span><img width="432" height="409" alt="image" src="Image_329.png"/></span></p><p class="s14" style="padding-left: 28pt;text-indent: -1pt;text-align: center;">All components meet criteria for CR</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s104" style="padding-top: 6pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">PR</p><p class="s14" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">PR in at least one component and all other components are either CR, MD* (bone marrow), PR (soft tissue or bone), or NI# in any other component; no component with PD</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s130" style="padding-top: 5pt;padding-left: 140pt;text-indent: 0pt;text-align: center;">Determination of overall response</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s104" style="padding-top: 5pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">SD</p><p class="s14" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">SD in one component with no better than SD or NI# in any other component; no component with PD</p><p class="s104" style="padding-top: 7pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">MR</p><p class="s14" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">PR or CR in at least one component, but at least one other component with SD; no component with PD</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 21.9 <span class="s25">revised international neuroblastoma response Criteria</span></p><p class="s131" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 121%;text-align: left;">response abbreviations: Cr, complete response; md, minimal disease; mr, minor response; ni, not involved; pd, progressive disease; pr partial response; sd, stable disease.</p><p class="s131" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">* For bone marrow assessment only</p><p class="s131" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"># site not involved at study entry and remains uninvolved</p><p class="s131" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 126%;text-align: left;">source: data from park Jr et al. ‘revisions to the international neuroblastoma response Criteria: A Consensus statement From the national Cancer institute Clinical trials planning meeting’, Journal of Clinical oncology, (2017) Vol. 35, issue 22, pp.2580–2587</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">sufficiently sensitive to detect small pulmonary nodules. HL is staged according to Cotswold revision of the Ann Arbor classification (Table 21.3).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Biopsy is essential for diagnosis either from surgical excision of a node or by percu- taneous, image-guided core biopsy.</p><p class="s65" style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">18<span class="s44">F-fluorodeoxyglucose positron emission tomography (FDG PET) enables assess- ment of the metabolic activity of involved nodal groups and organs in addition to the anatomical evaluation obtained with CT or MRI.</span>2 <span class="s44">Whole body FDG PET/CT is now a standard investigation at both diagnosis and follow-up in paediatric and adolescent HL (Figure 21.10).</span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">Table 21.3 <span class="s25">Cotswolds revision of the Ann Arbor staging system for lymphoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3622pt" cellspacing="0"><tr style="height:15pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage i</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">single lymph node region involvement, including isolated splenic involvement</p></td></tr><tr style="height:15pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage ii</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">two or more lymph node regions involved on the same side of the diaphragm</p></td></tr><tr style="height:15pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iii</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Lymph node groups or lymph structures involved on both sides of the diaphragm</p></td></tr><tr style="height:57pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iV</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">discontinuous extra-nodal involvement:</p><p class="s27" style="padding-top: 1pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Liver lesions</p><p class="s27" style="padding-top: 1pt;padding-left: 7pt;padding-right: 51pt;text-indent: 0pt;line-height: 112%;text-align: left;">pulmonary lesions: nodule &gt;1 cm or &gt;three nodules &lt;1 cm size Bone or bone marrow involvement</p><p class="s27" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">Cns involvement</p></td></tr><tr style="height:15pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">A</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Absence of ‘B’ symptoms</p></td></tr><tr style="height:47pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">B</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">presence of at least one of:</p><p class="s88" style="padding-top: 1pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">unexplained weight loss of &gt;10% in six months</span></p><p class="s88" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">drenching night sweats</span></p><p class="s88" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">unexplained persistent or recurrent fever &gt;38°C</span></p></td></tr><tr style="height:26pt"><td style="width:35pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">e</p></td><td style="width:288pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;line-height: 112%;text-align: left;">involvement of a single extra-nodal site in continuity with nodal disease, except liver or bone marrow involvement—always implies stage iV disease</p></td></tr></table><p class="s21" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: justify;">source: Lister tA, Crowther d, sutcliffe sB et al. report of a committee convened to discuss the evaluation and staging of patients with hodgkin’s disease: Cotswolds meeting. <i>J Clin Oncol. </i>1989 nov;7(11):1630-6. doi: 10.1200/JCo.1989.7.11.1630.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="412" height="247" alt="image" src="Image_330.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.10 <span class="s25">Anterior mediastinal mass: (a) staging axial mr image of anterior mediastinal mass (short arrows) with corresponding fused pet/Ct; (b) showing FdG avidity (arrowheads), restaging following two cycles of chemotherapy; (c) mr image showing reduction in size, but persistent mediastinal disease; (d) fused pet/Ct image showing an excellent metabolic response to chemotherapy, with no residual FdG avidity.</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.6.3 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients are reassessed after two cycles of chemotherapy and again at end of treat- ment with CT or MRI of the neck, abdomen, and pelvis, with CT of the thorax if pulmonary disease was present at diagnosis, to assess anatomical response to chemo- therapy (Table 21.4).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A PET scan is also performed after two cycles of chemotherapy to assess metabolic response. It is recognized that both false positive and false negative PET findings can be seen if the PET scan is performed too soon after completion of the chemotherapy cycle and hence at least a two-week gap between the end of chemotherapy and the PET study being performed is recommended. Ongoing clinical trials utilize PET response after two cycles of chemotherapy to determine if radiotherapy may be omitted. The presence of any persistent FDG PET avid nodes or organs after two cycles of chemo- therapy denotes an inadequate response and therefore radiotherapy will be adminis- tered to all involved nodes, as defined by the initial staging investigations.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In the first year following end of treatment, in addition to clinical examination, it is recommended that abdominal US be performed as a surveillance tool, initially four times a year, decreasing in frequency in the third year following end of treatment.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.6.4 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: right;">Radiotherapy is given to patients with HL who fail to respond adequately to two courses of chemotherapy. A positive PET scan, or persistently enlarged nodes even if PET negative, is an indication for radiotherapy on completion of chemotherapy. The duration of chemotherapy is based on initial stage rather than response to treatment. Current radiotherapy is based on CT planning (Figure 21.11). A planning CT scan is performed for target volume definition, optimization of the plan, and dosimetry of normal tissues. If it is possible to have therapy radiographers present at the reassessment PET/CT</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Table 21.4 <span class="s25">imaging assessment of response to therapy in childhood and adolescent lymphoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6694pt" cellspacing="0"><tr style="height:26pt"><td style="width:103pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">Local complete remission (local Cr)</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">residual tumour volume ≤5% reference volume at initial staging residual tumour volume ≤2 mL</p></td></tr><tr style="height:36pt"><td style="width:103pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">Local complete remission unconfirmed (local Cru)</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">no local Cr and:</p><p class="s88" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">residual tumour volume ≤25% reference volume</span></p><p class="s88" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">residual tumour ≤2 mL</span></p></td></tr><tr style="height:36pt"><td style="width:103pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">Local partial remission (local pr)</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">no local Cr or local Cru and:</p><p class="s88" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">residual tumour volume ≤50% reference volume</span></p><p class="s88" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">residual tumour volume is ≤5 mL</span></p></td></tr><tr style="height:26pt"><td style="width:103pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Local no change (local nC)</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">no local Cr or local Cru or local pr and:</p><p class="s88" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">no local progression</span></p></td></tr><tr style="height:26pt"><td style="width:103pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Local progression (local pro)</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">residual tumour volume &gt;125% of reference volume or significantly increases compared with best previous response</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="414" height="258" alt="image" src="Image_331.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.11 <span class="s25">radiotherapy images. (a) planning drr to show complete anterior field covering neck, supraclavicular, and superior mediastinal nodal areas. (b) simulator check film confirming correct field placement. (c) planning drr of anterior boost field used to achieve dose homogeneity. (d) isodose plans showing dose distribution in axial, coronal, and sagittal planes. (e) dose volume histograms confirming good coverage of target volumes and acceptable doses to organs at risk.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: right;">scan to place skin markers, and use a flat couch top with the patient in the treatment pos- ition, it is possible to use the CT component of the PET/CT scan for treatment planning rather than perform a repeat CT scan for planning purposes in the treatment department. The current European Hodgkin trial (EuroNet: PHL C2 trial) no longer treats all involved areas at diagnosis but rather targets radiotherapy to residual metabolically active sites only. The nodal groups are identified on CT. The whole length of lymph node chains, for example down the mediastinum, are treated, but if there has been a good shrinkage of an initial bulky mass it is sufficient to use the residual width as the</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">GTV, and not necessary to treat the whole width at diagnosis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">21.7 <span class="h4">Primary bone tumours: osteosarcoma and Ewing’s sarcoma</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.7.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Osteosarcoma (OS) is the commonest malignant paediatric primary bone tumour, characterized histologically by the presence of malignant mesenchymal cells that pro- duce immature bone or osteoid. It is rare in young children, the peak incidence of primary osteosarcoma is in adolescents between the ages of 15–19 years with 75% occurring before the age of 20. It becomes rarer again in adult life, although secondary osteosarcoma is recognized as a complication of previous radiotherapy, Paget’s disease</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">of bone in the elderly, and germline abnormalities such as Li-Fraumeni and Werner syndrome. Males are affected more frequently.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There are many histological subtypes; however, the commonest, high-grade cen- tral osteosarcoma (also known as classic or conventional OS) accounts for &gt;90% of cases. Whilst it can affect any bone, the majority of cases arise in the appendicular skeleton, most commonly around the knee (up to 75% cases) or proximal humerus. Involvement of axial and craniofacial tumour sites increase with age. Presentation is typically delayed, patients complaining of localized pain and swelling often attributed to trivial injury. Referred pain felt in the knee may mask the presentation of a proximal femoral lesion.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The Ewing family of tumours are a rare group of paediatric small blue round cell tu- mours arising from primitive neural elements, which includes classic Ewing’s sarcoma (ES) of bone, soft tissue ES, and peripheral primitive neuroectodermal tumours (pPNET). ES is more common than OS in young children and the second most common primary bone tumour in adolescents, with the median age at diagnosis being 15 years. Cases con- tinue to be seen into adult life. Pain is the presenting symptom in most cases, which typic- ally persists through the night and, as in OS, is often attributed to trivial injury or growing pains. Additional symptoms include swelling and constitutional signs such as fever.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Patients with bone tumours should be managed at designated supraregional bone tumour units. Patients should be referred to such a centre for diagnosis when the suspicion is raised, rather than being imaged and biopsied close to home in general orthopaedic units.</p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.7.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Plain films in two planes are the initial investigation in most cases of suspected pri- mary bone tumour. Appearances of OS are variable, with classical OS typically having a mixed sclerotic/lytic appearance involving the metaphysis of a long bone, often ac- companied by an aggressive periosteal reaction and soft tissue mass. Extension into the diaphysis and/or epiphysis is common, occasionally in association with a patho- logical fracture; this is associated with an increased risk of local recurrence owing to the dissemination of tumour cells into the surrounding tissues.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: right;">In ES, the extremity bones (50% of all cases) followed by the pelvis, ribs, and vertebrae are most commonly affected (Figures 21.12 and 21.13). Tumours involving long bones typ- ically have an aggressive permeative, lytic appearance within the diaphysis, often accom- panied by a soft tissue mass; however, up to a quarter of lesions are sclerotic at presentation. For both OS and ES, further local site staging with MRI, including the whole ana- tomical compartment, the involved bone, and adjacent joint should be performed. MRI is used to evaluate local extent due to its multiplanar capabilities and superior soft tissue resolution, with emphasis on defining intra- and extraosseous tumour extent, and involved tissue compartments that will ultimately influence the sur- gical approach. MRI is also useful in the detection of skip lesions (defined as sec- ondary tumour foci occurring simultaneously within the same bone) seen in up to 25% of OS cases, contralateral lesions, and in defining the relationship of tumour to nearby neurovascular structures. CT is routinely used in addition to MRI for pelvic tumours and is often helpful in cases of diagnostic uncertainty, allowing better</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="295" alt="image" src="Image_332.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.12 <span class="s25">Antero-posterior chest radiograph showing a large soft tissue mass within the right hemithorax exerting mass effect with lytic destruction of the right sixth rib (arrowhead).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">visualization of microcalcification, periosteal new bone formation, and cortical de- struction (Figure 21.13). Further staging includes CT chest and whole body MRI which has superseded technetium-99m (<span class="s22">99m</span>Tc)-phosphonate bone scan. Around 20–25% of ES patients have metastatic disease at presentation, involving the lung (10%), bone/bone marrow (10%), combinations, or others (5%).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="205" alt="image" src="Image_333.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.13 <span class="s25">ewing’s sarcoma. (a) unenhanced Ct chest demonstrating a large mass occupying the right hemithorax (short arrows) and destruction of the lateral sixth rib (filled arrowheads). (b) Coronal stir mr image of the chest better depicts the nature of the soft tissue mass (long arrows) which is arising from the lateral sixth rib (empty arrowhead).</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Histological confirmation requires bone biopsy, which will be performed at the des- ignated bone tumour treatment centre and should only be done after local imaging of the affected bone. The approach taken should be discussed with the bone tumour surgeon to avoid contamination of unaffected soft tissue compartments and to ensure resection of the biopsy tract at primary surgery.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Whilst not part of routine staging, FDG PET has proven to be both sensitive and specific in detecting bone metastases, as well as being advantageous in assessment re- sponse to treatment; however, it has yet to become part of an international staging system for either OS or ES, owing to limited availability. There is also increasing evidence that whole body MRI combined with FDG PET improves the detection of bone and bone marrow metastases in children and adolescents compared with either imaging modality alone or standard skeletal scintigraphy, with earlier detection of intramedullary tumour deposits before osteoblastic responses occur which are neces- sary for uptake on a conventional bone scan.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Treatment of patients with ES and OS is influenced by disease stage. Several staging systems for bone tumours are in use; however, none are perfect or widely accepted. Whilst each system differs slightly, their universal aim is the identifi- cation of prognostic factors influencing both local recurrence rates and meta- static disease. Adverse prognostic factors include primary site, metastases, and age at presentation (&gt;15 years), tumour volume or diameter &gt;8 cm, elevated lac- tate dehydrogenase (LDH) levels, and poor histological response to induction chemotherapy.</p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.7.3 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Current treatment strategies rely on neoadjuvant chemotherapy with surgery for local disease control and all resectable metastases. Radiotherapy has only a limited role in the management of extremity OS, being reserved for inoperable disease or following incomplete resection. Radical radiotherapy may be used as the sole local control mo- dality in axial OS which is inoperable. Treatment planning is based on the extent of disease as determined by MRI.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ewing’s tumours are radiosensitive. Preoperative radiotherapy is considered in bor- derline cases based on their response to induction chemotherapy assessed using a var- iety of imaging modalities including CT, whole body MRI, FDG PET, and thallium studies. Radiotherapy may be used alone in cases where only intralesional surgery would be possible or where metastatic disease is present.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Prior to radiotherapy planning, careful consideration needs to be given to the positioning of the area to be treated to allow for adequate treatment with maximum sparing of uninvolved normal tissues. Limbs should be immobilized in custom-made shells and a planning CT scan undertaken. Target volumes are defined based on the initial diagnostic MRI. The GTV is the tumour extent demonstrated by imaging. The CTV includes an additional longitudinal margin of up to 3 cm in long bones, leaving an unirradiated corridor of skin and subcutaneous tissue in the limb to pre- vent the development of lymphoedema. Any surgical scars or drainage sites should be included in the radiation field to ensure all potential sites of microscopic disease are treated.</p><p class="s28" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.7.4 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Local response to treatment is best monitored with MRI. Dynamic contrast enhanced (DCE) MRI is reliable in OS and allows changes in tumour vascularity to be evalu- ated. However, it is less reliable in ES as remaining small tumour foci may be missed. In this setting sequential FDG PET assessment may be of value. The role of diffusion weighted MRI is still under evaluation. Metastatic disease can be assessed with an array of imaging techniques dependent on the site. This will include CT chest, total body MRI, FDG PET, and isotope bone scans.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Studies report that 30–40% of patients experience recurrent disease either locally, at a distance from the primary site, or a combination of the two. Recurrence is associated with a poor prognosis, worse still if disease recurs within two years of initial diagnosis. Current guidelines recommend follow-up for at least 15 years.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">21.8 <span class="h4">Soft tissue sarcomas: rhabdomyosarcoma and other types</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.8.1 <span class="s124">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Soft tissue sarcomas can be classified into two main groups: rhabdomyosarcoma (RMS) and a variety of other (non-RMS) soft tissue sarcomas. RMS is the com- monest childhood soft tissue sarcoma, with almost two-thirds of cases diagnosed in children aged six years or under. It is a highly malignant tumour arising from primitive mesenchymal cells prior to their differentiation into striated muscle. Histologically there are two main subtypes. About 75% are embryonal rhabdo- myosarcoma (eRMS). Alveolar rhabdomyosarcoma (aRMS) carries a worse prog- nosis and is diagnosed on the basis of characteristic morphology and a high level of myogenin positivity on immunohistochemistry. There are many other types of soft tissue sarcoma encountered in children and young people, grouped together as non-RMS soft tissue sarcoma and including synovial cell carcinoma, fibrosarcoma, and malignant fibrous histiocytoma. As far as imaging goes, RMS and non-RMS soft tissue sarcomas can be considered together, as imaging is more dependent on ana- tomical site than histological type.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Clinical presentation is usually with a mass within the affected body region, in add-</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">ition to disturbances in body function by an enlarging tumour, or lymphadenopathy. RMS can arise almost anywhere within the body except bone, the more commonly affected sites involve the head and neck (40%), the genitourinary system (30%), and the extremities (16%).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: right;">Within the head and neck, a distinction is drawn between those tumours confined to the orbit which carry a very good prognosis, and other sites which are divided into parameningeal (50%) and non-parameningeal primary sites (50%). Parameningeal tu- mours are sited near the skull base, and there is a tendency for intracranial spread to occur through the neural and vascular foramina. Such sites include the nasopharynx, nasal cavity, and paranasal sinuses, middle ear and mastoid, infratemporal fossa, and pterygopalatine fossa. Non-parameningeal sites include the oral cavity, cheek, and larynx. Genitourinary primary sites are divided into bladder and prostate primary sites, and non-bladder/prostate sites including the vulva, vagina, and cervix in girls and</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">paratesticular tissues in boys (Figure 21.14).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="284" height="235" alt="image" src="Image_334.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.14 <span class="s25">rhabdomyosarcoma. (a) post-gadolinium sagittal t1-weighted mr image of a partly cystic, partly solid bladder rhabdomyosarcoma. (b) doppler us of the left scrotum with a large, vascular paratesticular rhabdomyosarcoma. (c) post-gadolinium axial t1- weighted mr of a homogenously enhancing, solid right labial rhabdomyosarcoma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Age and site at presentation differ for the subtypes, eRMS typically presenting in the younger children with orbital or other head and neck or genitourinary primaries, whilst aRMS tends to affect older children and adolescents involving the extremities.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">21.8.2 <span class="s124">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Initial diagnostic investigations will be guided by the site of primary tumour and its associated symptoms and signs. Genitourinary RMS is typically imaged with US in the first instance, followed by CT or MRI to assess extent and nodal involvement, whilst head and neck and extremity primaries are best imaged with MRI owing to its superior soft tissue resolution.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Approximately 20% of patients present with metastases at diagnosis. Evaluation for metastatic disease includes CT chest and <span class="s22">99m</span>Tc-diphosphonate bone scan reflecting the propensity of RMS to metastasize to lung and bone. Bone marrow aspirate and trephine are also essential to diagnose bone marrow involvement. More focused staging inves- tigations will depend on the knowledge of spread from specific primary sites, for ex- ample CSF sampling required in cases of cranial parameningeal tumours. PET/CT is now recognized as useful in the staging of RMS, and in quantifying disease activity in non-RMS soft tissue tumours. The main staging system for risk stratification is the IRSG (Intergroup Rhabdomyosarcoma Study Group) system, which defines four categories based on the extent of spread at diagnosis and volume of residual disease following ini- tial surgery.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Group I: primary complete resection with clear margins.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Group II: complete resection but positive margins on histology.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Group III: macroscopic residual tumour or biopsy only.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Group IV: distant metastases at diagnosis.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="154" alt="image" src="Image_335.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.15 <span class="s25">radiotherapy images. this patient had a parameningeal (left parapharyngeal) embryonal rhabdomyosarcoma, treated by an intensity modulated arc therapy technique with a simultaneous integrated boost. isodose distribution in (a) axial, (b) coronal, and (c) right para-sagittal planes, showing ptV 42.5 Gy (outer margin) and ptV 50.4 Gy (inner margin). the colour wash is set at 95% of 42.5 Gy, demonstrating excellent conformality with the ptV.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Full risk stratification takes into account the size of the tumour (5 cm or less in max- imum diameter, or greater than 5 cm), age, histology, site, and lymph node involve- ment as well as IRS group.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.8.3 <span class="s124">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy is indicated for the majority of patients with RMS (Figure 21.15). Exceptions include very young children, IRS group I, or IRS group II or III where there is a secondary complete resection. The target volume definition is usually based on the size of the primary tumour at diagnosis. Exceptions to this include tumours which ex- tend into a body cavity without direct invasion, and shrink back to the tissue of origin with chemotherapy. For example, a chest wall tumour may extend significantly into the pleural cavity. Following a good response to chemotherapy it is still necessary to irradiate all of the chest wall initially involved, but not the lung, which occupies the intrathoracic space previously occupied by tumour. The pretreatment T1 postcontrast MRI is usually the optimum imaging study for defining the GTV. These images can be fused with the planning CT scan performed with the patient immobilized as necessary in the treatment position (Figure 21.16). The CTV is usually the GTV plus 1 cm, but adjustments need to be made for areas of possible subclinical extension (such as the full thickness of the skull base in parameningeal cases) or if there are natural barriers to spread, and to include scars, drain sites, and biopsy tracts.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">21.8.4 <span class="s124">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Response to therapy in RMS is usually with the same imaging modality used at diag- nosis. However, if the original imaging modality used was CT, MRI should be con- sidered to reduce the use of ionizing radiation. The response to chemotherapy is not as important a prognostic factor as was thought previously. Imaging of the primary site</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="121" alt="image" src="Image_336.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 21.16 <span class="s25">radiotherapy Ct/mr fusion. (a) shows axial mri left paraspinal rhabdomyosarcoma extending through the chest wall at diagnosis (arrowed). (b) shows the fused image set. (c) shows the post-chemotherapy radiotherapy planning Ct scan. the original gross tumour volume can be delineated on scan (a), and then modified as necessary on scan (c).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">should also include assessment of regional lymph nodes as routine lymph node sam- pling at surgery is not advocated in most cases. If there is a definite residual mass after therapy, FDG PET/CT imaging may be useful to identify persistent metabolic activity, or an image-guided biopsy may be undertaken to differentiate between residual active disease and fibrosis or scarring. Often there is a residual abnormality on imaging but without mass effect, in which case PET will probably be unhelpful.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">21.9 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Malignant disease in children is uncommon.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Childhood tumours are a pathologically heterogeneous group.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Children with a suspected malignancy should be assessed at a designated paedi- atric oncology centre.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">An age-appropriate approach is required for both imaging and radiotherapy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Close multidisciplinary team working is vital for success.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Arumugam S</b>, <b>Manning-Cork NJ</b>, <b>Gains JE, et al. </b>(2019). The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review. <i>Clinical Oncology </i>(Royal College of Radiologists), <b>31</b>:182–190. doi: 10.1016/j.clon.2018.11.031. Epub 1 Dec 2018.</p><p class="s75" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">Brisse HJ<span class="s74">, </span>McCarville MB<span class="s74">, </span>Granata C, et al. <span class="s74">(2011). </span>International Neuroblastoma Risk Group Project. <span class="s74">Guidelines for imaging and staging of neuroblastic tumors: consensus report</span></p><p class="s74" style="padding-left: 18pt;text-indent: 0pt;text-align: left;">from the International Neuroblastoma Risk Group Project. <i>Radiology</i>, <b>261</b>(1): 243–257. doi: 10.1148/radiol.11101352. Epub 17 May 2011.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Casali PG</b>, <b>Bielack S</b>, <b>Abecassis N, et al. </b>(2018). Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i>, <b>29</b>: 79–95.</p><p class="s74" style="padding-top: 4pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Cohn SL</b>, <b>Pearson AD</b>, <b>London WB, et al. </b>(2009). INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. <i>Journal of Clinical Oncology</i>, <b>27</b>: 289–297. doi: 10.1200/JCO.2008.16.6785. Epub 1 Dec 2008.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Dumba M</b>, <b>Jawad N</b>, <b>McHugh K </b>(2015). Neuroblastoma and nephroblastoma: a radiological review. <i>Cancer Imaging</i>, <b>15</b>: 5.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Gerrand C</b>, <b>Athanasou N</b>, <b>Brennan B, et al. </b>(2016). UK guidelines for the management of bone sarcomas. <i>Clinical Sarcoma Research</i>, <b>6</b>: 7.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Louis DN</b>, <b>Perry A</b>, <b>Reifenberger G</b>, <i>et al. </i>(2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. <i>Acta Neuropathologica</i>, <b>131</b>: 803–820. doi: 10.1007/s00401-016-1545-1. Epub 9 May 2016.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Matthay KK</b>, <b>Maris JM</b>, <b>Schleiermacher G, et al. </b>(2016). Neuroblastoma. <i>Nature Reviews Disease Primers</i>, <b>2</b>: 16078. doi: 10.1038/nrdp.2016.78.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Metzger ML</b>, <b>Mauz-Körholz C </b>(2019). Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. <i>British Journal of Haematology</i>, doi: 10.1111/bjh.15789. 6 Feb 2019. Review.</p><p class="s75" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Park K<span class="s74">, </span>van Rijn R<span class="s74">, </span>McHugh K <span class="s74">(2008). The role of radiology in paediatric soft tissue sarcomas.</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Cancer Imaging</i>, <b>8</b>: 102–115.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Park JR</b>, <b>Bagatell R</b>, <b>Cohn SL, et al. </b>(2017). Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. <i>Journal of Clinical Oncology</i>, <b>35</b>: 2580–2587. doi: 10.1200/ JCO.2016.72.0177. Epub 4 May 2017. Review.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Skapek SX</b>, <b>Ferrari A</b>, <b>Gupta AA, et al. </b>(2019). Rhabdomyosarcoma. <i>Nature Reviews Disease Primers</i>, <b>5</b>: 1. doi: 10.1038/s41572-018-0051-2. Review.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Toma P</b>, <b>Granata C</b>, <b>Rossi A, et al. </b>(2007). Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. <i>Radiographics</i>, <b>27</b>: 1335–1355.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>van den Heuvel-Eibrink MM</b>, <b>Hol JA</b>, <b>Pritchard-Jones K, et al. </b>(2017). Rationale for the treatment of Wilms’ tumour in the UMBRELLA SIOP-RTSG 2016 protocol. <i>Nature Reviews Urology</i>, <b>14</b>: 743–752.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Reference</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">1. <b>Monclair T</b>, <b>Brodeur GM</b>, <b>Ambros PF, et al. </b>(2009). The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. <i>Journal of Clinical Oncology</i>,</p><p class="s75" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">27<span class="s74">: 298–303.</span></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part26.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part28.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
